A Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AP303 Following 2-week Oral Administration in Healthy Chinese Participants
Latest Information Update: 24 Oct 2024
At a glance
- Drugs AP 303 (Primary)
- Indications Diabetic nephropathies; Kidney disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Shanghai Alebund Pharmaceuticals
- 29 May 2024 Status changed from not yet recruiting to completed.
- 18 Mar 2024 New trial record